SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Alexion Pharmaceuticals, Inc. (ALXN)
An SI Board Since October 1997
Posts SubjectMarks Bans Symbol
824 29 0 ALXN
Emcee:  Larry Liebman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
349Just a scratch! Idiot Knight, I just cut of your arm! Wha? So you did. Well ckeokalani'nui-9/12/2003
348<i>Pretty hefty dilution (in the English sense of the term) -</i> Anigel bates-9/12/2003
347Alexion Pharmaceuticals Reports the Amelioration of Asthma Symptoms With Anti-C5nigel bates-9/8/2003
346COMMA trial Now, that is of course mind-boggling. They reduced the death-rate iIcebrg-9/2/2003
345Alexion Pharmaceuticals Reports Presentation of Additional Data From Its Pexeliznigel bates-9/2/2003
344BIRMINGHAM, Ala., Aug. 27 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, InIcebrg-8/27/2003
343Tom >>just so i'm clear about this: aren't these the studies presIcebrg-8/21/2003
342Icebrg, just so i'm clear about this: aren't these the studies presentetom r. phillips-8/21/2003
341Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary PeIcebrg-8/20/2003
340Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Icebrg-8/20/2003
339finance.yahoo.com Missed primary endpoint, up for the year....... finance.yahoscaram(o)uche-8/20/2003
338thanks- looks like we know the following: 1. there is no alternative therapy to Madharry-8/12/2003
337LOL.Madharry-8/12/2003
336That will work fine so long as you are not roped to the guide. lol, sorta.keokalani'nui-8/12/2003
335Hey, you're my guide.scaram(o)uche-8/12/2003
334Yes I do--unless there is another strong correlation between periop and subsequekeokalani'nui-8/12/2003
333Wilder Don't you think that the distribution between death and MI will mattIcebrg-8/12/2003
332>>Perhaps someone could tell me: when the company sets up a phase III do tkeokalani'nui-8/12/2003
331In all CCs for period from day they started Primo until data released they were Miljenko Zuanic-8/12/2003
330Perhaps someone could tell me: when the company sets up a phase III do they not Madharry-8/11/2003
329Miljenko, Thanks for taking the time to respond so thoroughly. Yes, even at cuIan@SI-8/11/2003
328Ian, <<And we still have Pex reducing deaths without introducing adverse Miljenko Zuanic-8/11/2003
327msnbc.com Not directly related to ALXN, but of general interest to treating disIan@SI-8/11/2003
326That I can completely agree with. But that's not new. It's just anotIan@SI-8/11/2003
325He <i>is</i> right. And you are right. I am right too. No one wrokeokalani'nui-8/11/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News